Gregory C. Critchfield, MD, MS
Dr. Critchfield joined the Sera Prognostics Board of Directors on August 2010, became Chairman in April 2011, and was appointed as Sera’s CEO in November 2011. Before joining Sera, Dr. Critchfield was president of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as senior vice president/chief medical and science officer at Corning Clinical Laboratories/Quest Diagnostics. Dr. Critchfield has also served as an independent director on the boards of Saladax Biomedical, BioTrove, Biocius, Integrated Diagnostics, Nodality, Metamark Genetics, Lantos Technologies, Epic Sciences, and Condor Therapeutics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.